全文获取类型
收费全文 | 75101篇 |
免费 | 5657篇 |
国内免费 | 2497篇 |
专业分类
耳鼻咽喉 | 433篇 |
儿科学 | 1568篇 |
妇产科学 | 1077篇 |
基础医学 | 11044篇 |
口腔科学 | 1153篇 |
临床医学 | 5705篇 |
内科学 | 11261篇 |
皮肤病学 | 1275篇 |
神经病学 | 5490篇 |
特种医学 | 1003篇 |
外国民族医学 | 19篇 |
外科学 | 5245篇 |
综合类 | 8841篇 |
现状与发展 | 12篇 |
预防医学 | 5449篇 |
眼科学 | 1242篇 |
药学 | 13811篇 |
16篇 | |
中国医学 | 4293篇 |
肿瘤学 | 4318篇 |
出版年
2023年 | 1051篇 |
2022年 | 1317篇 |
2021年 | 2330篇 |
2020年 | 2529篇 |
2019年 | 2862篇 |
2018年 | 2758篇 |
2017年 | 2620篇 |
2016年 | 2643篇 |
2015年 | 2677篇 |
2014年 | 4702篇 |
2013年 | 6322篇 |
2012年 | 5142篇 |
2011年 | 5549篇 |
2010年 | 4539篇 |
2009年 | 3807篇 |
2008年 | 3425篇 |
2007年 | 2903篇 |
2006年 | 2444篇 |
2005年 | 2153篇 |
2004年 | 1877篇 |
2003年 | 1681篇 |
2002年 | 1331篇 |
2001年 | 1149篇 |
2000年 | 850篇 |
1999年 | 841篇 |
1998年 | 670篇 |
1997年 | 626篇 |
1996年 | 538篇 |
1995年 | 512篇 |
1994年 | 455篇 |
1993年 | 426篇 |
1992年 | 387篇 |
1991年 | 364篇 |
1990年 | 323篇 |
1989年 | 268篇 |
1988年 | 259篇 |
1987年 | 192篇 |
1985年 | 887篇 |
1984年 | 1158篇 |
1983年 | 905篇 |
1982年 | 1041篇 |
1981年 | 948篇 |
1980年 | 730篇 |
1979年 | 664篇 |
1978年 | 471篇 |
1977年 | 387篇 |
1976年 | 432篇 |
1975年 | 337篇 |
1974年 | 214篇 |
1973年 | 225篇 |
排序方式: 共有10000条查询结果,搜索用时 421 毫秒
41.
探讨岗位价值评估方法在医院人力资源的管理过程中的应用和意义。采用国际岗位价值评估系统(IPE)对A医院现有140个岗位进行岗位价值评估,并利用岗位评分对人力资源管理问题进行剖析。A医院岗位评估分数的总趋势和总分布结果显示,岗位评估分值曲线现呈较平滑的递减趋势,这表明A医院职能处室内部各类岗位的岗位价值不存在明显差异。从各个职能处室内部来看,内部岗位评价结果分布比较均匀,说明部门内部分工相对合理。岗位价值评价有助于增强医院薪酬分配的公平性,提高薪酬的激励性,也有利于优化医院管理制度,推动医院可持续发展。 相似文献
42.
《Journal of thoracic oncology》2020,15(7):1210-1222
IntroductionThe safety and efficacy of bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β “trap“) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1), was evaluated in patients with advanced NSCLC.MethodsThis expansion cohort of NCT02517398, an ongoing, phase 1, open-label trial, includes 80 patients with advanced NSCLC that progressed after platinum doublet therapy or after platinum-based adjuvant or neoadjuvant treatment and those who also have not received previous immunotherapy. Patients were randomized at a one-to-one ratio to receive either bintrafusp alfa 500 mg or the recommended phase 2 dosage of 1200 mg every 2 weeks. The primary end point was the best overall response (by Response Evaluation Criteria in Solid Tumors 1.1 as adjudicated by independent review committee) and was assessed by the objective response rate (ORR).ResultsA total of 80 patients were randomized to receive bintrafusp alfa 500 or 1200 mg (n = 40 each). Median follow-up was 51.9 weeks (IQR, 19.6–74.0). The ORR in all patients was 21.3% (17 of 80). The ORR was 17.5% (seven of 40) and 25.0% (10 of 40) for the 500 mg dose and the 1200 mg dose (recommended phase 2 dose), respectively. At the 1200 mg dose, patients with PD-L1–positive and PD-L1–high (≥80% expression on tumor cells) had ORRs of 36.0% (10 of 27) and 85.7% (six of seven), respectively.Treatment-related adverse events occurred in 55 of the 80 patients (69%) and were graded as greater than or equal to 3 in 23 of the 80 patients (29%). Of the 80 patients, eight (10%) had a treatment-related adverse event that led to treatment discontinuation; no treatment-related deaths occurred.ConclusionsBintrafusp alfa had encouraging efficacy and manageable tolerability in patients with NSCLC previously treated with platinum. 相似文献
43.
Cinnamaldehyde (CA) is an essential component of cinnamon (Cinnamomum cassia Presland), which is often used as a flavoring condiment in beverages, pastries, perfumes, etc. Cinnamon is also used as herbal medicine in China and Southeast Asia to treat rheumatoid arthritis. However, the molecular mechanism is unclear. In this study, we aim to investigate its anti-inflammatory effects against Rheumatoid arthritis (RA) using activated macrophages (Raw246.7) in vitro and adjuvant arthritis rats (AA) in vivo. The results demonstrated that CA significantly reduced synovial inflammation in AA rats, possibly due to suppression of the expressions of pro-inflammatory cytokines, especially the IL-1β. Further investigation found that CA also suppressed the activity of HIF-1α by inhibiting the accumulation of succinate in cytoplasm. As we know, the reduction of HIF-1α nucleation slows down IL-1β production, because HIF-1α activates the expression of NLRP3, which is involved in the assembly of inflammasome and processing of IL-1β. In addition, CA also inhibited the expression of the succinate receptor GPR91, which in turn inhibited the activation of HIF-1α. In conclusions, our results suggested that CA might be a potential therapeutic compound to relieve rheumatoid arthritis progress by suppressing IL-1β through modulating succinate/HIF-1α axis and inhibition of NLRP3. 相似文献
44.
背景与目的:组蛋白修饰是非常重要的表观遗传修饰形式,组蛋白甲基化修饰酶基因的异常表达与多种疾病及癌症的发生、发展有关。探讨直肠癌患者肿瘤组织的组蛋白甲基转移酶hSETD1A表达水平与临床预后的相关性。方法:选取2012年1月-2014年6月福建省肿瘤医院有详细临床资料和预后随访信息的直肠癌患者肿瘤组织切除标本141例及癌旁组织标本50例。采用免疫组织化学法检测h SETD1A的表达情况,分析其与直肠癌临床病理学特征(年龄、性别、肿瘤大小、T分期、淋巴结转移、神经累及等参数)及预后的关系。结果:肿瘤组织中h SETD1A的阳性表达率明显高于癌旁组织(75.2%vs26.0%,P<0.001)。此外,其阳性率的高低还与患者性别及肿瘤分化程度的不同相关(P=0.009)。而与年龄、肿瘤大小、T分期、淋巴结转移、TNM分期、神经累及、脉管癌栓、血清癌胚抗原(carcinoembryonic antigen,CEA)及CA19-9水平无关。生存分析结果显示,h SETD1A阳性组的5年生存率明显低于h SETD1A阴性组(64.4%vs 76.5%,P=0.036)。多因素COX回归分析显示,h SETD1A表达和T分期、淋巴结转移状况(N分期)是直肠癌的独立预后因素。结论:肿瘤组织hSETD1A的表达水平与直肠癌患者的预后密切相关。 相似文献
45.
目的研究某院耐碳青霉烯类肠杆菌科细菌(CRE)在细菌耐药方面的分子流行病学特征,为CRE的防控提供依据。方法收集某院2013—2017年细菌室保存的CRE,对其进行多位点序列分型(MLST)、药敏试验、全基因序列测定,选取部分CRE中携带的碳青霉烯耐药基因进行基因环境分析。结果共收集62株CRE,成功复活51株;其中耐碳青霉烯类肺炎克雷伯菌(CRKP)30株,耐碳青霉烯类大肠埃希菌(CREC)9株,耐碳青霉烯类阴沟肠杆菌(CRECL)6株,耐碳青霉烯类其他肠杆菌6株。CRKP MLST主要包括3株ST147、2株ST11;CREC MLST主要包括3株ST167;CRECL MLST主要包括3株ST93、2株ST88。51株CRE对氨苄西林、头孢噻肟的耐药率最高,均为100%。耐碳青霉烯类耐药基因分布:1株携带blaKPC-2,14株携带blaIMP-4,18株携带blaNDM-1,22株携带blaNDM-5,2株携带blaNDM-9,10株携带blaOXA-1,10株携带blaOXA-10,2株携带blaOXA-23,2株携带blaOXA-66。分析blaNDM-1、blaNDM-5、blaNDM-9、blaIMP-4不同菌种的基因环境,发现几种耐药基因各自的基因环境都与已报道的基因环境相似,无明显的菌种间差异性。结论耐药基因通过水平传播能稳定存在于不同的CRE菌株中,对医院感染防控造成一定的威胁。 相似文献
46.
Cynthia J. Hines Thomas J. Lentz Lauralynn McKernan Pranav Rane Christine Whittaker 《Journal of occupational and environmental hygiene》2019,16(2):120-128
Bisphenol A is a commercially important chemical used to make polycarbonate plastic, epoxy resins, and other specialty products. Despite an extensive body of in vitro, animal and human observational studies on the effects of exposure to bisphenol A, no authoritative bodies in the U.S. have adopted or recommended occupational exposure limits for bisphenol A. In 2017, the National Institute for Occupational Safety and Health published a Draft process for assigning health-protective occupational exposure bands, i.e., an airborne concentration range, to chemicals lacking an occupational exposure limit. Occupational exposure banding is a systematic process that uses both quantitative and qualitative toxicity information on selected health effect endpoints to assign an occupational exposure band for a chemical. The Draft process proposes three methodological tiers of increasing complexity for assigning an occupational exposure band. We applied Tier 1 (based on the Globally Harmonized System of Classification and Labelling) and Tier 2 (based on authoritative sources/reviews) to assign an occupational exposure band to bisphenol A. Under both Tier 1 and 2, the occupational exposure band for bisphenol A was “E” (<0.01?mg/m3), an assignment based on eye damage. “E” is the lowest exposure concentration range, reserved for chemicals with high potential toxicity. If eye damage was excluded in assigning an air concentration exposure range, then bisphenol A would band as “D” (>0.01 to 0.1?mg/m3) under Tier 1 (based on reproductive toxicity and respiratory/skin sensitization) and under Tier 2 (based on specific target organ toxicity-repeated exposure). In summary, Tiers 1 and 2 gave the same occupational exposure band for bisphenol A when eye damage was included (“E”) or excluded (“D”) as an endpoint. 相似文献
47.
48.
SNAIL1 employs β-Catenin-LEF1 complexes to control colorectal cancer cell invasion and proliferation
49.
50.
目的:探究蛋白磷酸酶2A(CIP2A)在子宫内膜样腺癌中的表达情况及临床意义。方法:选取2011年1月至2014年3月行手术切除并经病理证实的50例子宫内膜样腺癌(EAC)及同期行门诊刮宫术获取的40例正常增生期子宫内膜(NE)组织标本。应用RT-PCR、Western blot法检测EAC和NE组织中CIP2A mRNA及蛋白水平,免疫组化法检测CIP2A阳性表达情况。分析CIP2A在EAC和NE组织中的表达差异及与子宫内膜样腺癌临床病理特征的关系。采用Kaplan-Meier法分析CIP2A不同表达水平对患者预后生存的影响,通过COX分析预后独立危险因素。结果:免疫组化染色显示:CIP2A在子宫内膜样腺癌中呈高表达,阳性着色定位于细胞浆和细胞核中,EAC组织中CIP2A阳性表达率显著高于NE组织(P<0.01)。RT-PCR和Western blot检测显示EAC组织中CIP2A mRNA及蛋白表达水平高于NE组织(P<0.01)。CIP2A表达与EAC的组织学分级、FIGO分期、宫颈管受累情况、p53表达及Ki-67增殖指数有关(P<0.05)。Kaplan-Meier法生存分析显示EAC患者5年无病生存率为92.0%、总生存率为88.0%;CIP2A表达、组织学分级、FIGO分期、肌层浸润深度、附件转移、脉管内癌栓及Ki-67增殖指数与患者预后不良相关(P<0.05)。多因素分析显示,组织学分级、FIGO分期及脉管内癌栓是影响子宫内膜样腺癌患者预后生存的独立危险因素(P<0.05)。结论:CIP2A在子宫内膜样腺癌中呈高表达,与患者总生存率下降相关,并非影响患者预后的独立危险因素。 相似文献